source
- Phase 1 trial of HS-10504 shows encouraging responses in EGFR C797S mutant lung cancerHS-10504, an investigational therapy, was evaluated in a Phase 1 study in patients with non-small cell lung cancer harboring the EGFR C797S mutation after progression on prior tyrosine kinase inhib…
- Microbiome startup Kanvas Biosciences secures $48 million to advance immunotherapy and malnutrition therapiesKanvas Biosciences announced it has closed a $48 million financing round to fund development of microbiome-based treatments targeting cancer immunotherapy response and severe malnutrition. The cap…